Cetuximab, Trametinib, Cft1946
Melanoma, Solid Tumors, Nsclc, Crc, Atc
Active Not Recruiting
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
―